Evidence map›Paper›PMID 40853386›Full record

ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2025

Six-month outcomes of half-fluence photodynamic therapy combined with intravitreal Aflibercept injection for pachychoroid neovasculopathy.

Yosuke Fukuda, Satomi Shiose, Shoji Notomi, Yusuke Maehara, Kenichiro Mori, Kumiko Kano, Keijiro Ishikawa, Koh-Hei Sonoda

Abstract read
PubMed Publisher
In one paragraph

Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yosuke FukudaDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Satomi ShioseDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan. asshyharyu@gmail.com.ORCID http://orcid.org/0000-0003-4662-9755
Shoji NotomiDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Yusuke MaeharaDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Kenichiro MoriDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Kumiko KanoDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Keijiro IshikawaDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.
Koh-Hei SonodaDepartment of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan.

Funding

Japan Society for the Promotion of Science London JP21K09702
6 · The paper itself

Abstract

purposeThis study aimed to assess the six-month outcomes of patients with pachychoroid neovasculopathy (PNV) treated with half-fluence photodynamic therapy (PDT) along with a single intravitreal aflibercept injection (IVA) and to identify factors linked to persistent or recurrent subretinal fluid (SRF).

methodsThis retrospective study included consecutive treatment-naïve PNV patients who received initial treatment with IVA and half-fluence PDT and were followed up for more than six months. Patient data, including sex, age, and baseline best-corrected visual acuity (BCVA), and imaging data, including optical coherence tomography (OCT), OCT angiography, and fundus autofluorescence (FAF), were retrospectively collected. BCVA, central macular thickness (CMT), and central choroidal thickness (CCT) were compared before and after the treatment. Additionally, we investigated factors linked to persistent or recurrent SRF.

results63 eyes of 63 patients were included in this study. The mean BCVA before treatment was 0.13 ± 0.23 logMAR, which improved to 0.04 ± 0.18 after six months. Additionally, the CMT and CCT before treatment significantly decreased. Persistent or recurrent SRF was observed in 21 patients (33%). These patients were older and demonstrated worse baseline BCVA, larger macular neovascularization (MNV), and greater hyperfluorescent areas on FAF.

conclusionAlthough half-fluence PDT along with IVA effectively improved BCVA, CMT, and CCT in patients with PNV, one-third of the patients required additional treatment due to persistent SRF. Older age, larger MNV, and worse baseline BCVA were linked to persistent SRF, underscoring the requirement for tailored treatment strategies.

Indexed as

ChoroidChoroidal NeovascularizationPhotochemotherapyReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVisual AcuityAgedAged, 80 and overAngiogenesis InhibitorsFemaleFluorescein AngiographyFollow-Up StudiesFundus OculiHumansIntravitreal InjectionsMaleafliberceptAngiogenesis InhibitorsPhotosensitizing AgentsReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVerteporfinAnti-vascular endothelial growth factor therapyFundus autofluorescenceOptical coherent tomography angiographyPachychoroid neovasculopathyPhotodynamic therapy

Identifiers

PMID40853386

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.